Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,820,964 to the Company with claims covering the use of pharmaceutical compositions comprising anabasum for the treatment of multiple fibrotic diseases, including the Company’s lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis as well as others. Read more >>